EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

miR ‐199a/214 cluster enhances prostate cancer sensitiveness to nimotuzumab via targeting TBL1XR1

Sheng Hu, Qiang Zhou, Qiang Lu, Xi Guo, Yong Wang, Yi-Xing Duan iD

The Kaohsiung Journal of Medical Sciences · 2023

DOI: 10.1002/kjm2.12758 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, 2023. Verfasst von Sheng Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hunan Provincial People's Hospital (The first-affiliated hospital of Hunan normal university), Changsha, Hunan Province, P.R. …. Hauptthemen laut MEDLINE: MicroRNAs, Prostatic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) is a significant health concern affecting men worldwide. Previous studies have shown that nimotuzumab, a drug targeting the epidermal growth factor receptor (EGFR), can effectively inhibit cancer progression. Here, we aimed to explore the role of miR‐199a/214 cluster in mediating the inhibitory effect of nimotuzumab on the development of PCa. In this study, we conducted an MTT assay to assess cell proliferation and utilized flow cytometry to evaluate cell apoptosis and cell cycle arrest. To investigate the molecular mechanisms underlying the effects of nimotuzumab on prostate cancer development, we focused on the miR‐199a‐5p and miR‐214‐3p miRNA clusters. The TargetScan Human database was used to predict the binding sites between miR‐199a‐5p or miR‐214‐3p and the 3'‐UTR of the transducin (β)‐like 1 X‐linked receptor 1 (TBL1XR1) mRNA. To confirm the direct interaction and binding between miR‐199a‐5p or miR‐214‐3p and the 3'‐UTR of TBL1XR1 mRNA, we performed luciferase reporter assays. Our findings demonstrated that nimotuzumab exerted a significant dosage‐dependent suppression of PCa cell proliferation and facilitated PCa cell apoptosis and cell cycle arrest. Concurrently, nimotuzumab obviously impeded the activity of Wnt/β‐catenin and EGFR signaling pathways in PCa cells. We also observed downregulation of miR‐199a‐5p and miR‐214‐3p in PCa cells. Overexpression of miR‐199a/214 cluster inhibited PCa cell viability and enhanced cell apoptosis. Furthermore, we found that miR‐199a/214 cluster augmented the inhibitory effect of nimotuzumab on PCa cell proliferation and promoted its ability to induce apoptosis and cell cycle arrest. This effect was reversed upon TBL1XR1 overexpression, indicating that TBL1XR1 is involved in the regulatory pathway of miR‐199a/214 and nimotuzumab in PCa cells. We further revealed that TBL1XR1 was overexpressed in PCa and was identified as a downstream target of the miR‐199a/214 cluster. In nimotuzumab‐treated PCa cells, the overexpression of miR‐199a/214 markedly inhibited Wnt/β‐catenin and EGFR signaling, and this effect was also rescued by TBL1XR1 overexpression. In summary, our data indicated that miR‐199a/214 cluster play a crucial role in enhancing the inhibitory effect of nimotuzumab on PCa development by downregulating TBL1XR1 and modulating Wnt/β‐catenin and EGFR signaling pathways. These findings offer a novel therapeutic approach for the treatment of prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsProstatic NeoplasmsMaleHumansbeta CateninGene Expression Regulation, NeoplasticCell ProliferationErbB ReceptorsRNA, MessengerCell Line, TumorRepressor ProteinsReceptors, Cytoplasmic and NuclearAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

cell apoptosismiR-199a/214 clusternimotuzumabproliferationprostate cancer

Substanzen

beta CateninMicroRNAsErbB ReceptorsRNA, MessengerRepressor ProteinsReceptors, Cytoplasmic and NuclearnimotuzumabAntibodies, Monoclonal, HumanizedTBL1XR1 protein, humanMIRN214 microRNA, human

Autor:innen und Institutionen

  • Department of Urology, Hunan Provincial People's Hospital (The first-affiliated hospital of Hunan normal university), Changsha, Hunan Province, P.R. China.

ORCID-Profile: Yi-Xing Duan

Zitieren

APA

Hu, S., Zhou, Q., Lu, Q., Guo, X., Wang, Y., & Duan, Y. X. (2023). miR ‐199a/214 cluster enhances prostate cancer sensitiveness to nimotuzumab via targeting TBL1XR1. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.12758

Vancouver

Hu S, Zhou Q, Lu Q, Guo X, Wang Y, Duan YX. miR ‐199a/214 cluster enhances prostate cancer sensitiveness to nimotuzumab via targeting TBL1XR1. The Kaohsiung Journal of Medical Sciences. 2023. doi:10.1002/kjm2.12758

BibTeX
@article{Hu2023,
  author = {Hu, Sheng and Zhou, Qiang and Lu, Qiang and Guo, Xi and Wang, Yong and Duan, Yi-Xing},
  title = {miR ‐199a/214 cluster enhances prostate cancer sensitiveness to nimotuzumab via targeting TBL1XR1},
  journal = {The Kaohsiung Journal of Medical Sciences},
  year = {2023},
  doi = {10.1002/kjm2.12758}
}
Kostenlos starten →